Stem Cell Clinic

Stem Cell Manufacturing Market Likely to Experience a Tremendous Growth in Near Future || Thermo Fis – PharmiWeb.com

DBMR has added a new report titledGlobal Stem Cell Manufacturing Marketwith data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This Global Stem Cell Manufacturing Market report is quite useful to find out the general market conditions and tendencies. It also estimates the probable market for a new product to be launched in the market. This also Report has compiled to provide various market aspects such as size, share, trends, dynamics, growth, sales, and industry analysis. The competitive analysis taken place in this Global Stem Cell Manufacturing Market report include strategic profiling of key market players, their core competencies, their strong and weak points, and competitive landscape of the market which supports businesses illustrate their individual strategies.

The Global Stem Cell Manufacturing Market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Stem Cell Manufacturing Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

Market Analysis and Insights: Global Stem Cell Manufacturing Market

Stem cell manufacturing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 18.59 billion by 2027 growing at a CAGR of 6.42% in the above-mentioned forecast period. The growing awareness towards diseases like cancer, hematopoietic disorders and degenerative disorders is going to drive the growth of the stem cell manufacturing market.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-manufacturing-market&pm

The Objective of This Report:

The Global Stem Cell Manufacturing Market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the Global Stem Cell Manufacturing Market. The report focuses on well-known providers in the Global Stem Cell Manufacturing Market industry, market segments, competition, and the macro environment.

Under COVID-19 Outbreak, how the Global Stem Cell Manufacturing Market Industry will develop is also analyzed in detail in this report.

Competitive Landscape and Stem Cell Manufacturing Market Share Analysis

Stem cell manufacturing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to stem cell manufacturing market.

The major players covered in the stem cell manufacturing market report are Thermo Fisher Scientific., Merck KGaA, BD, JCR Pharmaceuticals Co., Ltd., Organogenesis Inc, Osiris, Vericel Corporation, AbbVie Inc., AM-Pharma B.V., ANTEROGEN.CO.,LTD., Astellas Pharma Inc., Bristol-Myers Squibb Company, FUJIFILM Cellular Dynamics, Inc., RHEACELL GmbH & Co. KG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., ViaCyte,Inc., VistaGen Therapeutics Inc, GlaxoSmithKline plc, DAIICHI SANKYO COMPANY, LIMITED, among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Increase in the research and development activities in pharmaceutical and biotechnology sector, stem cell therapy including cell therapy and gene therapy along with animal biotechnology sector for the production of better yield is likely to accelerate the growth of the stem cell manufacturing market in the forecast period of 2020-2027.

People ethics such as the embryonic stem cell research violates respect for human life and downward pricing of product owing to commodity is likely to hamper the growth of the stem cell manufacturing market in the above mentioned forecast period.

Global Stem Cell Manufacturing Market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographical expansions, technological innovations in the market.

Global Stem Cell Manufacturing Market Scope and Market Size

Stem cell manufacturing market is segmented on the basis of product, application and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Stem Cell Manufacturing Market Country Level Analysis

Stem cell manufacturing market is analysed and market size insights and trends are provided by country, product, application and end users as referenced above.

The countries covered in the stem cell manufacturing market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the stem cell manufacturing market due to growing research in stem cell, robust research infrastructure, rising public-private funding, permission to support the clinical evaluation of stem cells for various applications along with rising public awareness on the therapeutic potency of stem cells, while Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2020 to 2027 due to the ongoing expansion & innovation of healthcare infrastructure across emerging Asian countries, the presence of supportive regulatory frameworks for stem cell research and manufacturing, and growing public-private initiatives to encourage public awareness about stem cell-based treatment.

The country section of the stem cell manufacturing market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Stem cell manufacturing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for stem cell manufacturing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the stem cell manufacturing market. The data is available for historic period 2010 to 2018.

Table of Contents:

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-manufacturing-market&pm

Insights of the Market in Report

1. The study provides an in-depth analysis of the Global Stem Cell Manufacturing Market along with the current trends and future estimations to elucidate the imminent investment pockets. 2. Comprehensive analysis of the factors that drive and restrict the market growth is provided in the report. 3. Comprehensive quantitative analysis of the industry is provided for the period of 2018-2025 to assist stakeholders to capitalize on the prevailing market opportunities. 4. Extensive analysis of the key segments of the industry helps in understanding the trends in types of Global Stem Cell Manufacturing Market across Glob. 5. Key market players and their strategies have been provided to understand the competitive outlook of the Global Stem Cell Manufacturing Market industry

Customization Available: Global Stem Cell Manufacturing Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Note: If You Have Any Special Requirements, Please Let Us Know and We Will Offer You the Report as You Want.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @Corporatesales@databridgemarketresearch.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Excerpt from:
Stem Cell Manufacturing Market Likely to Experience a Tremendous Growth in Near Future || Thermo Fis - PharmiWeb.com

Hematopoietic Stem Cell Transplantation (HSCT) Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or…

Global Hematopoietic Stem Cell Transplantation (HSCT) industry report about In-depth Research, estimates Revenue, and forecasts Growth Details in segments, regional, and research scope, historical data, Key Player and Growth Value.

The Global Hematopoietic Stem Cell Transplantation (HSCT) Market 2020 analysis provides a basic summary of the trade as well as definitions, classifications, applications and business chain structure. The worldwide Hematopoietic Stem Cell Transplantation (HSCT) marketing research is provided for the international markets together with development trends, competitive landscape analysis, and key regions development standing. Development policies and plans are mentioned similarly as producing processes and value structures are analyzed. This report additionally states import/export consumption, supply and demand Figures, cost, price, revenue, and gross margins.

Premium Insights on Hematopoietic Stem Cell Transplantation (HSCT) Market 2020 with Market Players Positioning Get Exclusive Sample PDF Copy:https://inforgrowth.com/sample-request/6544617/hematopoietic-stem-cell-transplantation-hsct-marke

Major Classifications of Hematopoietic Stem Cell Transplantation (HSCT) Market:

Major Key players covered in this report:Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc.

By Product Type:Allogeneic, Autologous

By Applications:Peripheral Blood Stem Cells Transplant (PBSCT), Bone Marrow Transplant (BMT), Cord Blood Transplant (CBT)

Get Chance of 20% Extra Discount, If your Company is Listed in Above Key Players List https://inforgrowth.com/discount/6544617/hematopoietic-stem-cell-transplantation-hsct-marke

Impact of COVID-19: Hematopoietic Stem Cell Transplantation (HSCT) Market report analyses the impact of Coronavirus (COVID-19) on the Hematopoietic Stem Cell Transplantation (HSCT) industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Hematopoietic Stem Cell Transplantation (HSCT) market in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get Sample Table of Content PDF of COVID-19/CoronaVirus Impact Analysis of Hematopoietic Stem Cell Transplantation (HSCT) Market 2020. https://inforgrowth.com/CovidImpact-Request/6544617/hematopoietic-stem-cell-transplantation-hsct-marke

This Market Study covers the Hematopoietic Stem Cell Transplantation (HSCT) Market Size across segments. It aims at estimating the market size and the growth potential of the market across segments by component, data type, deployment type, organization size, vertical, and region. This Hematopoietic Stem Cell Transplantation (HSCT) study also includes an in-depth competitive analysis of the key market players, along with their company profiles, key observations related to product and business offerings, recent developments, and key market strategies.

Attributes such as new development in Hematopoietic Stem Cell Transplantation (HSCT) market, Total Revenue, sales, annual production, government norm, and trade barriers in some countries are also mentioned in detail in the report. Hematopoietic Stem Cell Transplantation (HSCT) Report discusses about recent product innovations and gives an overview of potential regional market shares.

Reason to purchase Hematopoietic Stem Cell Transplantation (HSCT) market report:

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT: Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USA Contact Name: Rohan S. Email:[emailprotected] Phone: +1-909-329-2808 UK: +44 (203) 743 1898

Go here to see the original:
Hematopoietic Stem Cell Transplantation (HSCT) Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or...

Elixirgen Therapeutics planning to begin Phase I/II Clinical Trials of its COVID-19 Vaccine Candidate EXG-5003 at Fujita Health University – BioSpace

BALTIMORE, Sept. 1, 2020 /PRNewswire/ -- Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery, development and commercialization of therapies for genetic diseases and vaccines, announced that Fujita Health University has received acontract from the Japan Agency for Medical Research and Development (AMED) to initiate Phase I/II clinical trials of the company's COVID-19 vaccine candidate, EXG-5003. Clinical trials are expected to begin at Fujita Health University Hospital in Aichi, Japan in Q1 2021.

EXG-5003 is a temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein. EXG-5003 was optimized for intradermal injection withpotential dose-sparing and safety benefits.

About Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics, Inc. is a Baltimore-based biotechnology company, which is focused on curing humanity's ailments through innovations in gene and cell therapy, including stem cell therapy. Elixirgen Therapeutics, Inc. is now applying its RNA technology to the development of a COVID-19 vaccine.For more information visit http://www.ElixirgenTherapeutics.com

About Fujita Health University

Fujita Health University plays a major role in treating COVID-19 patients and conducting its clinical trials in Japan. For more information visit http://www.fujita-hu.ac.jp/en/

Forward-Looking Statements

This press release may contain "forward-looking" statements, including statements regarding the potential to develop a COVID-19 vaccine and our planned clinical relationship with Fujita Health University. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in vaccine research and development. Any forward-looking statements in this press release speak only as of the date of this press release, and Elixirgen Therapeutics undertakes no obligation to update or revise the statementsin the future, even if new information becomes available.

Contact Media Relations Elixirgen Therapeutics, Inc. (443) 869-5420 Media@ElixirgenTherapeutics.com

View original content:http://www.prnewswire.com/news-releases/elixirgen-therapeutics-planning-to-begin-phase-iii-clinical-trials-of-its-covid-19-vaccine-candidate-exg-5003-at-fujita-health-university-301121932.html

SOURCE Elixirgen Therapeutics

View original post here:
Elixirgen Therapeutics planning to begin Phase I/II Clinical Trials of its COVID-19 Vaccine Candidate EXG-5003 at Fujita Health University - BioSpace

Cell Counting Market worth $14.5 billion by 2025 according to a new research report – WhaTech

The cell counting market is projected to reach USD 14.5 billion in 2025 from USD 10.4 billion in 2020, at a CAGR of 6.7 % during the forecast period.

The market growth is largely driven by factors such as growing funding for cell-based research, rising incidence of chronic and infectious diseases, growing biotechnology and biopharmaceutical industries, the development of enhanced solutions and improved image analysis, and the growing use of high-throughput flow cytometry and automated hematologyanalyzers. On the other hand, the high cost of cell analysis is expected to hinder market growth to a certain extent.

According to MarketsandMarkets - [247 Pages Report] The global cell counting market is projected to reach USD 14.5 billion in 2025 from USD 10.4 billion in 2020, at a CAGR of 6.7 % during the forecast period.

Cell Counting Market by Product (Instruments (Spectrophotometer, Hemocytometer, Flow Cytometer, HematologyAnalyzers), Consumables (Reagent, Microplate)), Cancer, Stem Cell Research, End User (Pharmaceutical, Hospital, Research) - Global Forecast to 2025

Download a PDF Brochure @ http://www.marketsandmarkets.com/pdfdown=157450728

The medical application segment is expected to grow at the highest CAGR during the forecast period

On the basis of application, the cell counting market is segmented into research, medical, and industrial applications. The medical application segment will grow at the highest CAGR in the cell counting market.

Increasing government initiatives in stem cell research and the wide usage of cell counting in research are the major factors driving the growth of the research applications segment during the forecast period.

The hospitals and diagnostic laboratories segment is expected to grow at the highest CAGR during the forecast period

On the basis of end users, the cell counting market is segmented into research institutes, hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies and CROs, and other end users. The hospitals and diagnostic laboratories will grow at the highest CAGR during the forecast period.

The high growth of this segment can primarily be attributed to the growing regulatory approvals for cell culture-based vaccines, increasing pharmaceutical R&D expenditure, and commercial expansion of various pharmaceutical companies.

Request a Sample Pages @ http://www.marketsandmarkets.com/request=157450728

The Asia Pacific region is expected to account for the largest share of the cell counting market during the forecast period

The APAC region is expected to grow at the highest CAGR during the forecast period. The large growth of this segment can be attributed to factors such as the growing number of proteomics, genomics, and stem cell research activities; increasing research funding; increasing investments by pharmaceutical and biotechnology companies; and the growing trend of research infrastructure modernization.

Key Market Players

The major companies in the cell counting market include Thermo Fisher Scientific Inc (US), Merck KGaA (Germany), PerkinElmer Inc (US), Olympus Corporation (Japan), HORIBA Ltd (Japan), Logos BiosystemsInc (South Korea), Corning Incorporated (US), Tecan Trading AG (Switzerland), Abbott (US), General Electric Company (US), Boule Diagnostics AB (Sweden), Becton, Dickinson and Company (US), Tip Biosystems (Singapore), Agilent Technologies Inc (US), Sysmex Corporation (Japan), Siemens Healthcare Private Limited (Germany), Danaher (US), Diconex (Argentina), Beckman Coulter Inc (US), Nexcelom Bioscience LLC (US), ChemoMetec A/S (Denmark), Bio-Rad Laboratories Inc (US), Advanced Instruments (US), R&D Systems, Inc. (US), and Cole-Parmer Instrument Company LLC (US)

Recent Developments:

Speak to Analyst @ http://www.marketsandmarkets.com/speakto=157450728

This email address is being protected from spambots. You need JavaScript enabled to view it.

View original post here:
Cell Counting Market worth $14.5 billion by 2025 according to a new research report - WhaTech

Global Musculoskeletal Disorder Stem Cell Therapy Market 2020 Upcoming Trends, Latest Innovation, Advance Technology and Forecast 2025 – Owned

Global Musculoskeletal Disorder Stem Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 combines the essentials, definitions, categorization, and analysis of significant features. A latest extensive, professional market study brings data on the Musculoskeletal Disorder Stem Cell Therapy market which is related to market competitors and recognized players for the forecast period from 2020 to 2025. The market study is segmented by, trends, latest analytics, top players, application usage, and various important geographical dividends. The beginning section of the report contains the basic detailed information about the concerned market. The report studies the worldwide markets vital regional market demands. It covers the analysis of market position and market size. Further, it provides a layout with regard to the market dynamics, by pinpointing several aspects comprising limitations, value chain, and drivers.

The various new and innovative manufacturing processes for the manufacturing of Musculoskeletal Disorder Stem Cell Therapy are being adopted by the market players on a large scale. The research helps you to achieve positive growth and allow different methods for maximizing your profit. Moving forward, the competitive landscape of the Musculoskeletal Disorder Stem Cell Therapy market in the world is given by profiling the major participants of the market in order to identify the leading players in the market. The study contains a general effective framework, restrictions, and a total explanation of the previous data close by the investigated present and future needs.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/36571

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Region Segment Analysis of the Market:

Based on segmentation, the global Musculoskeletal Disorder Stem Cell Therapy market report is made up of an in-depth investigation of the leading regions, including North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). The research was provided including developments, leading growth status, landscape analysis, and segmentation with product types and applications. The cost-profit is broken down regionally, leading to analysis results that explain the market condition in a specific geographical area and can be used to make focused market policies. The number of crucial regions that the marketing research is finished in is North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). These are the top-grossing regions that have revealed the utmost development in each side of technology, businesses, population, industry, and more.

Some of the leading key companys covered for this research are Osiris Therapeutics, Medi-post, NuVasive, Takeda (TiGenix)

The report highlights product types which are as follows: llogeneic, Autologous, etc.

The report highlights top applications which are as follows: uscle disease, Skeletal disease, etc.

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-musculoskeletal-disorder-stem-cell-therapy-market-36571

Reason to Buy Musculoskeletal Disorder Stem Cell Therapy Market Report:

Moreover, the report includes social and opinion research that comprises information about individuals or organizations. Marketing strategies and different channels have been listed here. It uncovers the gaps and opportunities to derive the most relevant insights from our research document to gain global Musculoskeletal Disorder Stem Cell Therapy market size.

Customization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: [emailprotected] Web: http://www.researchstore.biz

Click Here For Similar Reports:

Global Axle Market 2020 Key Players Data, Revenue, Future Development, Trend and Competitive Landscape Analysis by 2025

Global Cocoa Butter Fats Market 2020 Key Players, Comprehensive Research, SWOT Analysis and Forecast by 2025

Global Foldable Walker Market 2020 Opportunities, Challenges, Key Players, Trend and Forecast by 2025

Global Foldable Baby Stroller Market 2020 Industry Analysis by Key Players, Product Type, Application, Regions and Forecast to 2025

View post:
Global Musculoskeletal Disorder Stem Cell Therapy Market 2020 Upcoming Trends, Latest Innovation, Advance Technology and Forecast 2025 - Owned

Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I – GlobeNewswire

September 01, 2020 07:00 ET | Source: Orchard Therapeutics (Europe) Limited

Data on all eight patients demonstrate sustained engraftment and supranormal IDUA enzyme expression

Translation of metabolic correction to clinical outcomes in first two patients continues to support potential of hematopoietic stem cell gene therapy in a second neurometabolic disorder

Data support planned initiation of registrational trial in 2021

BOSTON and LONDON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics(Nasdaq: ORTX), a global gene therapy leader, today announced additional interim data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, an investigationalex vivoautologous hematopoietic stem cell (HSC) gene therapy in development for the treatment of mucopolysaccharidosis type I (MPS-I) at theSan Raffaele Telethon Institute for Gene Therapy(SR-Tiget) inMilan, Italy. The readout from the primary endpoint at one year of follow-up is expected in 2021. Today's results are being shared virtually in an invited oral presentation at the 46th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT).

We continue to see encouraging data from the ongoing clinical trial in MPS-I, including promising preliminary clinical effects on motor development, acquisition of cognitive skilIs and growth in the first two patients that were treated now 1.5 and 2 years ago, respectively. Additionally, new preliminary analyses of radiological outcome measures suggest that treatment with OTL-203 leads to stabilization or improvement in disease-related neurological abnormalities, as measured by brain and spine MRI, which we look to confirm with longer follow-up, saidMaria Ester Bernardo, M.D., Ph.D., principal investigator at SR-Tiget. "These data, taken together with those from clinical studies of HSC gene therapy for other metabolic disorders and leukodystrophies, support the potential for this therapeutic approach to correct a wide spectrum of multisystemic manifestations of the disease, bringing clinically meaningful benefits for patients.

Interim Study Results

Eight patients with the severe Hurler subtype of MPS-I had been treated with OTL-203 in the ongoing proof-of-concept study, which completed enrollment in December 2019. As of July 2020, all patients had been followed for a minimum of six months, with the longest follow-up extending out to 24 months. Treatment with OTL-203 was generally well-tolerated with a safety profile consistent with the selected conditioning regimen. Consistent with previous analyses, treatment across all eight patients continued to demonstrate:

We continue to see positive trends in all biomarker and clinical measures as we follow patients in the OTL-203 proof of concept study for longer periods of time, saidBobby Gaspar, M.D., Ph.D., chief executive officer of Orchard. With a growing amount of data to support advancing this program, we have recently convened a panel of disease experts to develop a design for a registrational trial that we intend to take to the regulators in advance of initiating the study in 2021 and ultimately progressing towards commercialization.

About OTL-203 and MPS-I

Mucopolysaccharidosis type I (MPS-I) is a rare, inherited neurometabolic disease caused by a deficiency of the alpha-L-iduronidase (IDUA) lysosomal enzyme, which is required to break down sugar molecules called glycosaminoglycans (also known as GAGs). The accumulation of GAGs across multiple organ systems results in symptoms including neurocognitive impairment, skeletal deformity, loss of vision and hearing, and cardiovascular and pulmonary complications. MPS-I occurs at an overall estimated frequency of one in every 100,000 live births. There are three subtypes of MPS-I; approximately 60 percent of children born with MPS-I have the most severe subtype, called Hurler syndrome, and rarely live past the age of 10 when untreated.

Treatment options for MPS-I include hematopoietic stem cell transplant and chronic enzyme replacement therapy, both of which have significant limitations. Though early intervention with enzyme replacement therapy has been shown to delay or prevent some clinical features of the condition, it has only limited efficacy on neurological symptoms. OTL-203 is an investigationalex vivoautologous hematopoietic stem cell gene therapy being studied for the treatment of MPS-I. Orchard was granted an exclusive worldwide license to intellectual property rights to research, develop, manufacture and commercialize the gene therapy program for the treatment of MPS-I developed by theSan Raffaele Telethon Institute for Gene TherapyinMilan, Italy.

About Orchard

Orchard Therapeuticsis a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Ourex vivoautologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and theSan Raffaele Telethon Institute for Gene Therapy inMilan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters inLondonandU.S.headquarters inBoston. For more information, please visitwww.orchard-tx.com, and follow us onTwitterandLinkedIn.

Availability of Other Information About Orchard

Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (TwitterandLinkedIn), including but not limited to investor presentations and investor fact sheets,U.S. Securities and Exchange Commissionfilings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking Statements

This press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as anticipates, believes, expects, plans, intends, projects, and future or similar expressions that are intended to identify forward-looking statements. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, the therapeutic potential of Orchards product candidates, including the product candidates referred to in this release, Orchards expectations regarding the timing of clinical trials for its product candidates, including the product candidates referred to in this release, the timing of interactions with regulators and regulatory submissions related to ongoing and new clinical trials for its product candidates, the timing of announcement of clinical data for its product candidates, and the likelihood that such data will be positive and support further clinical development and regulatory approval of these product candidates. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development, its supply chain and commercial programs; the risk that Orchard will not realize the anticipated benefits of its new strategic plan or the expected cash savings associated with such plan; the risk that any one or more of Orchards product candidates, including the product candidates referred to in this release, will not be successfully developed, approved or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates or that long-term adverse safety findings may be discovered; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; and the risk of delays in Orchards ability to commercialize its product candidates, if approved. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter endedJune 30, 2020, as filed with theU.S. Securities and Exchange Commission(SEC), as well as subsequent filings and reports filed with theSEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

Investors Renee Leck Director, Investor Relations +1 862-242-0764 Renee.Leck@orchard-tx.com

Media Molly Cameron Manager, Corporate Communications +1 978-339-3378 media@orchard-tx.com

Here is the original post:
Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I - GlobeNewswire

Insights on the Human Microbiome Immunology Therapeutics Global Market to 2025 – Featuring Finch Therapeutics, MaaT Pharma & Merck Among Others -…

September 02, 2020 04:49 ET | Source: Research and Markets

Dublin, Sept. 02, 2020 (GLOBE NEWSWIRE) -- The "Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025" clinical trials has been added to ResearchAndMarkets.com's offering.

The scale and scope of microbiome research activity has now become one of the fastest growing areas in biology. The relevance that it has shown for the welfare of the society and pharmaceutical industry has led to the development of a transdisciplinary environment that is however conducive to innovation with a mission to abolish the limitations in the pharmaceutical industry through excellence in microbiome research, awareness and outreach. Over the years now, gut microbiome is estimated to implicate success for the various immunotherapies.

Microbiome's role in immunology practices is to transform world-class treatment into the medicine of today and tomorrow. It is highly recognizable that the healthcare issues that mankind is facing today is now bigger than any one solution. The treatment of certain diseases requires multiple options for the treatment and ultimately prevention. Therefore, the amalgamation of two different treatment paradigms i.e. microbiome and immunology are apparently delivering some medical benefits that millions of patients were in need for long period of time. The ways in which microbiome is understood and manipulated to serve the immunological aspects has given great interest to all the researchers.

The essential and usual concept of immunology depicts targeting the immune system of the body to provoke an immune response with huge impact but then the unsuccessful implication of immunology therapies driven treatments led to an exploration of several other basic concepts that could play an important role in boosting the immune system when combined. Looking forward, the microbiome community in the gut represented beneficial patterns with respect to further research. The area of microbiome research and its combination with immunological aspect for the disease treatment has produced a real excitement in the area of medical research and specifically microbiome research.

All over the world, the amalgamation of the two has been well accepted and appreciated by the patients, physicians and the clinicians. Investigation of all the working sides of microbiome and how it plays an important role in boosting the manipulated immune cells have recently started in large numbers as the technology available in the medical field allows to capture it accurately. To facilitate the microbiome and immunology community in order to extract the best and trending opportunities that are stemmed into the microbiome research, the experts from both the relevant disciplines are analyzing it through clinical researches and surveys. Further, the area is getting supported by 86 different clinical trials getting conducted in different countries.

The Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025 report summarizes the view of the wider opportunities that are associated microbiome community for the advancement of the scientific information regarding immunology. The science that is related to microbiome has high interdisciplinary and various opportunities that somehow have remained hidden in the medical world. It is believed that the opportunities and all the desirable tangible benefits microbiome is capable of delivering when combined with immunology is large and needs coordinated and constructive approach. The call to the two different sectors i.e. microbiology and immunology is estimated to unlock the potential and promising benefits of microbiome. The approach leading to the extraction of advantages if properly embedded in the microbiome and immunology research, the future benefits will be huge

Report Highlights:

Key Topics Covered:

1. Overview of Microbiome 1.1 Introduction to Microbiome 1.2 History & Evolution of Microbiome

2. Role of Microbiome in Human Body

3. Microbiome: Various Forms 3.1 Gut Microbiome 3.2 Lung Microbiome 3.3 Skin Microbiome 3.4 Microbiome in Other Parts of the Body

4. Mechanism of Microbiome Activity 4.1 Nature of Immune Response 4.1.1 Immunosuppressive Activity 4.1.2 Immunostimulatory Activity 4.2 Messengers Involves in Microbiome Mechanism 4.2.1 MAMPs/PAMPs 4.2.2 Microbial Metabolites As Messengers 4.2.3 Host Cytokines As Messengers 4.2.4 Immune Cells As Messengers

5. Technological Requirement for Microbiota 5.1 Technologies Used 5.1.1 iChip 5.1.2 Simulator of the Human Intestinal Microbial Ecosystem (SHIME) 5.1.3 Gut-on-a-Chip System 5.1.4 Colonic Stem Cell Construction 5.2 Harnessing & Engineering the Microbiome 5.2.1 Additive Approaches 5.2.2 Subtractive Approaches

6. Need for Microbiome Immunology

7. Therapeutic Applications of Microbiome Immunology 7.1 Microbiome Therapy 7.2 Precision Medicine 7.3 Drug discovery 7.4 Biomarkers & Therapy Optimization

8. Human Microbiota in Infectious Diseases 8.1 Infection with Clostridium Difficile 8.2 Infection with Helicobacter Pylori 8.3 Bacterial Vaginosis 8.4 Infection with HIV

9. The Human Microbiota & Liver Diseases 9.1 Non-Alcoholic Fatty Liver Disease (NAFLD) 9.2 Alcoholic Liver Diseases (ALD) 9.3 Liver Fibrosis & Cirrhosis

10. The Human Microbiota & Metabolic Disorders 10.1 Obesity 10.2 Type 2 Diabetes

11. The Human Microbiota & Other Diseases 11.1 Microbiota & Allergic Diseases 11.2 Microbiota & Psychiatric Diseases

12. Microbiome in Immuno Oncology 12.1 Role of Microbiome in Immuno Oncology 12.2 Microbiome Mechanism in Oncogenesis & Tumor Suppression

13. Microbiome Application by Cancer Types 13.1 Gastric Cancer 13.2 Colorectal Cancer 13.3 Esophageal Cancer 13.4 Hepatocellular Carcinoma 13.5 Melanoma 13.6 Solid Tumors

14. Industrial Approaches of Microbiome Therapy in Oncology 14.1 Bacterial Approaches 14.1.1 Fecal Microbiota Transplantation (FMT) 14.1.2 Synthetic Bacteria 14.1.3 Microbial Culture 14.2 Microbiome as Vaccine 14.3 Microbiome as Small Molecules 14.4 Microbiome Therapy using Phage Virus

15. Global Human Microbiome Market Analysis 15.1 Overview 15.2 Human Microbiome Market Segmentation 15.2.1 Regional Segmentation 15.2.2 Disease Based Segmentation 15.2.3 Segmentation by Application

16. Clinical Pipeline of Microbiome Based Therapy 16.1 Microbiome Modulators in Clinical Trial 16.2 Cancer Related Clinical Trials 16.2.1 Preclinical & Discovery Phase 16.2.2 Active Clinical Trials 16.3 Clinical Trial Related To FMT 16.3.1 Clinical Trial for Recurrent C. difficile 16.3.2 Clinical Trial for Inflammatory Bowel Disease (IBD) 16.3.3 Other FMT Related Clinical Trials

17. Global Microbiome Modulators Clinical Pipeline By Company, Indication & Phase 17.1 Research 17.2 Preclinical 17.3 Clinical 17.4 Phase-I 17.5 Phase-I/II 17.6 Phase-II 17.7 Phase-II/III 17.8 Phase-III

18. Marketed Microbiome Modulators Clinical Insight 18.1 Sodium Oligomannurarate - Shanghai Green Valley Pharmaceutical 18.2 Miya-BM

19. Global Microbiome Immunology Therapeutics Market Growth Drivers

20. Microbiome Technology - Investments, Acquisitions & Collaborations by Leading Microbiome Companies

21. Blockades in the Microbiome Immunology Market 21.1 Stable Engraftment 21.2 Development of Clinically Relevant Sensors 21.3 Robustness and Evolutionary Stability of Genetic Circuits 21.4 Regulation, Safety and Biocontainment

22. Global Microbiome Immunology Market Future Panorama

23. Competitive Landscape 23.1 4D Pharma 23.2 AbbVie 23.3 AstraZeneca plc 23.4 Biocodex 23.5 Bristol Mayer Squibb 23.6 Corebiome/Diversigen 23.7 Elogi Bioscience 23.8 Enterome 23.9 Ferring Pharmaceuticals 23.10 Finch Therapeutics 23.11 Maat Pharma 23.12 Merck 23.13 Microbiome Therapeutics 23.14 Novartis 23.15 OpenBiome 23.16 Pfizer 23.17 Rebiotix 23.18 Second Genome 23.19 Seres Therapeutics 23.20 Symberix 23.21 Takeda Pharmaceuticals 23.22 Vedanta Bioscience

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/d6z6gb

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post here:
Insights on the Human Microbiome Immunology Therapeutics Global Market to 2025 - Featuring Finch Therapeutics, MaaT Pharma & Merck Among Others -...